Biolase (BIOL)
(Delayed Data from OTC)
$0.06 USD
+0.01 (9.62%)
Updated Aug 30, 2024 03:29 PM ET
NA Value
NA Growth NA Momentum NA VGMBiolase (BIOL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.20 | $4.00 | $0.40 | 4,300.00% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Biolase comes to $2.20. The forecasts range from a low of $0.40 to a high of $4.00. The average price target represents an increase of 4% from the last closing price of $0.05.
Analyst Price Targets (2 )
Broker Rating
Biolase currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on four recommendations.
Of the three recommendations deriving the current ABR, two are Buy, representing 66.67% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 25%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BIOL.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 2 | 2 | 2 |
Buy | 2 | 2 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.33 | 2.33 | 1.75 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | The Benchmark Company | Bruce D Jackson | Strong Buy | Moderate Buy |
5/24/2024 | Maxim Group | Anthony V Vendetti | Strong Buy | Hold |
4/1/2024 | Ascendiant Capital Markets | Edward M Woo | Not Available | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 3 |
Average Target Price | $2.20 |
LT Growth Rate | NA |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 185 of 253 |
Current Quarter EPS Est: | NA |